Moreover, administration of the VEGF inhibitor bevacizumab to BC-bearing mice reduces the intratumor infiltration of protumor TAMs and MDSCs, as well as diminishing tumor vessel density and BC growth [90]. Here, VEGFA is linked to neoplasm.